Physician profile
Edgar Castillo
NPI 1851492847
$17,545.14
in general payments reported to CMS, 2019-2025
24 companies · $2,908 in 2025
The $2,908 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,157 · 2020: $775 · 2021: $2,266 · 2022: $2,218 · 2023: $2,892 · 2024: $3,329 · 2025: $2,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,917 · Consulting Fee: $200 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,917.01 |
| Consulting Fee | $200.00 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,458.57 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,165.19 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,727.43 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,501.21 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $1,323.60 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $1,216.33 | 2019-2025 | Uzedy, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $793.47 | 2019-2025 | Trintellix, Entyvio |
| Janssen Pharmaceuticals, INC | $782.53 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $762.25 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $697.88 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $545.82 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $509.08 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $466.73 | 2019-2022 | |
| Allergan, INC. | $371.42 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $244.21 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $218.99 | 2021 | |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $165.70 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $124.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.67 | 2023 | |
| Indivior INC. | $70.93 | 2023-2024 | Perseris |
| Shire North American Group INC | $43.43 | 2019 | |
| Novo Nordisk INC | $21.53 | 2020 | |
| Adlon Therapeutics L.P. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.